This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
by Zacks Equity Research
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
by Zacks Equity Research
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
by Zacks Equity Research
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
by Zacks Equity Research
IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval
by Zacks Equity Research
BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.
Myriad Genetics Shares Fall Despite Partnership With jscreen
by Zacks Equity Research
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch
by Zacks Equity Research
ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.
Paragon 28's Shares Rise After Launch of Phantom Fibula Nail System
by Zacks Equity Research
FNA unveils Phantom Fibula Nail System, a less invasive, next-gen solution for ankle fractures, offering enhanced precision, stability and better patient outcomes.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
by Zacks Equity Research
ABT delivers a strong underlying base business performance in the third quarter of 2024.
Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan
by Zacks Equity Research
CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
by Zacks Equity Research
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
by Zacks Equity Research
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
GE HealthCare's Shares Rise After the Launch of Versana Premier
by Zacks Equity Research
GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
All You Need to Know About Addus HomeCare (ADUS) Rating Upgrade to Buy
by Zacks Equity Research
Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare
by Zacks Equity Research
Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.
Addus HomeCare (ADUS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 12.50% and 1.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.